Table 3 Prescription by pharmacological groups

2020 n = 135

ACEIARB

ARNI

RAASi

Bb

MRA

SGLT2i

Admission

41(30.4)

23(17.0)

63(46.7)

85(63.0)

46(34.1)

17(12.6)

Discharge

47(34.8)

50(37.0)

96(71.1)

103(76.3)

74(54.8)

27(20.0)

p

0.418

< 0.001

< 0.001

0.004

< 0.001

0.002

Difference % (CI95%)

4.4(-4.5/13.4)

20.0(11.8/28.2)

24.4(14.9/34.0)

13.3(4.9/21.7)

20.7(12.3/29.2)

7.4(1.4/8.1)

2021 n = 261

ACEI/ARB

ARNI

RAASi

Bb

MRA

SGLT2i

Admission

98(37.5)

49(18.8)

147(56.3)

150(57.5)

99(37.9)

67(25.7)

Discharge

86(33.0)

101(38.7)

187(71.6)

220(84.3)

170(65.1)

112(42.9)

p

0.224

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Difference % (CI95%)

-4.5(-11.4/2.2)

19.9(14.5/25.3)

15.3(9.2/21.4)

49.6(38.9/60.3)

27.2(21.2/33.2)

17.2(12.2/22.3)

2022 n = 206

ACEI/ARB

ARNI

RAASi

Bb

MRA

SGLT2i

Admission

69(33.5)

40(19.4)

109(52.9)

103(50.0)

71(34.5)

78(37.9)

Discharge

60(29.1)

80(38.8)

140(68.0)

155(75.2)

136(66.0)

145(70.4)

p

0.253

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Difference % (CI95%)

-4.4(-11.0/2.3)

19.4(13.1/25.7)

15.1(8.3/21.8)

25.2(18.6/31.9)

31.5(24.9/38.2)

32.5(26.0/39.1)

2020–2022 n = 602

ACEI/ARB

ARNI

RAASi

Bb

MRA

SGLT2i

Admission

208(34.6)

112(18.6)

319(53.0)

338(56.1)

216(35.9)

162(26.9)

Discharge

193(32.1)

231(38.4)

423(70.3)

478(79.4)

380(63.1)

284(47.2)

p

0.281

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Difference % (CI95%)

-2.5(-6.7/1.7)

19.8(16.1/23.4)

17.3(13.2/21.4)

23.3(19.1/27.4)

27.2(23.3/31.2)

20.3(16.9/23.6)